Get started
Work

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Year: 2018
Type: article
Abstract: Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.
DOI: 10.1002/ajh.25338
Authors: Nicholas J. Short, Elias Jabbour, Maher Albitar, Marcos de Lima, Lia Gore, Jeffrey Jorgensen, Aaron C. Logan, Jae Park, Farhad Ravandi, Bijal Shah, Jerald Radich, Hagop Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, NeoGenomics (United States), University Hospitals of Cleveland, Children's Hospital Colorado, University of Colorado Cancer Center, University of California, San Francisco, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Fred Hutch Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2900007121
FWCI: 11.9
Cites: 76
Cited by: 136
Related to: 10